Catch up on the latest imaging research from the recent European Society of Cardiology (ESC) Congress.

Catch up on a variety of FDA news in radiology from the past week.

Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.

Catch up on a variety of FDA news in radiology from the past week.

Catch up on the top radiology content of the past week.

Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.

In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.

Catch up on the top radiology content of the past week.